Targeted radiofrequency ablation

Minimally invasive treatment provides fast pain relief for cancer patients

Retrieved on: 
Friday, March 26, 2021
Medicine, Clinical medicine, Medical specialties, Interventional radiology, Bone metastasis, Bone tumor, Cancer, Medication-related osteonecrosis of the jaw, Targeted radiofrequency ablation, Interventional oncology

FAIRFAX, Va., March 26, 2021 /PRNewswire/ --A minimally invasive treatment for patients whose cancer has spread to their bones provides quick and sustained pain relief and improves quality of life, according to a new study presented today at the Society of Interventional Radiology Annual Scientific Meeting.

Key Points: 
  • FAIRFAX, Va., March 26, 2021 /PRNewswire/ --A minimally invasive treatment for patients whose cancer has spread to their bones provides quick and sustained pain relief and improves quality of life, according to a new study presented today at the Society of Interventional Radiology Annual Scientific Meeting.
  • RFA is a minimally invasive treatment that uses radiofrequency waves to create heat that kills tumor cells and destroys nerve fibers to reduce or stop transmission of pain signals to the brain.
  • "As a result, we believe this treatment should be available to more patients with metastatic cancer earlier in their treatment path."
  • The research focused on lytic bone metastases, a common type of bone tumor found in many cancer patients, making the treatment an option for a wide range of cancer patients.

The Asia Pacific radiofrequency ablation devices market is anticipated to reach US$ 1,705.06 Mn by 2027 from US$ 699.62 Mn in 2019. The market is projected to grow at a CAGR of 12.1% from 2020 to 2027

Retrieved on: 
Saturday, May 23, 2020
Medicine, Medical specialties, Clinical medicine, Interventional radiology, Medical terminology, Radiofrequency ablation, Surgical oncology, Ablation, Targeted radiofrequency ablation

The Asia Pacific radiofrequency ablation devices market is anticipated to reach US$ 1,705.06 Mn by 2027 from US$ 699.62 Mn in 2019.

Key Points: 
  • The Asia Pacific radiofrequency ablation devices market is anticipated to reach US$ 1,705.06 Mn by 2027 from US$ 699.62 Mn in 2019.
  • The market is projected to grow at a CAGR of 12.1% from 2020 to 2027.
  • The radiofrequency ablation devices market growth is primarily attributed to the rising prevalence of chronic diseases, emerging applications of radiofrequency ablation technology, and increasing preference for minimally invasive procedures in Asia Pacific.
  • In 2019, the surgical oncology segment held the largest share of the Asia Pacific radiofrequency ablation devices market, by application, in 2019.

Insights on the Global Tumor Ablation Industry to 2027 - Drivers, Restraints, Opportunities & Threats - ResearchAndMarkets.com

Retrieved on: 
Monday, April 6, 2020
Surgery, Health, Oncology, Medical specialties, RTT, Medicine, Clinical medicine, Gastric antral vascular ectasia, Ablation, Pancreatic cancer, Cholangiocarcinoma, Cancer, Ectasia, Radiofrequency ablation, Targeted radiofrequency ablation

The "Tumor Ablation - Global Market Outlook (2018-2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Tumor Ablation - Global Market Outlook (2018-2027)" report has been added to ResearchAndMarkets.com's offering.
  • The Global Tumor Ablation market accounted for $394.66 million in 2018 and is expected to reach $1,253.33 million by 2027 growing at a CAGR of 13.7% during the forecast period.
  • Tumor ablation is a minimally invasive image-guided technique used in the treatment of the tumors in the liver, kidney, soft tissue and bone.
  • Tumor ablation has primarily been used for the treatment of oesophagal squamous cell dysplasia, gastric antral vascular ectasia, radiation proctopathy, cholangiocarcinoma, and pancreatic neoplasia.